Piper Sandler analyst Arvind Ramnani maintains Paycom Software (NYSE:PAYC) with a Overweight and raises the price target from $361 to $387.
FibroGen Sponsored Study Titled ‘A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participants Receiving Chemotherapy Treatment for Non-Myeloid Malignancies’ Posted To ClinicalTrials.gov; Study Not Yet Recruiting
https://clinicaltrials.gov/ct2/show/NCT05301517